

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

FOSUN PHARMA

复星医药

上海復星醫藥（集團）股份有限公司

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02196)

2026 THIRD QUARTERLY REPORT

This announcement is made pursuant to Rule 13.09(2) and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The following is the 2026 third quarterly report of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively the “**Group**”) (the “**2026 Third Quarterly Report**”) for the three months ended 30 September 2026 (the “**Reporting Period**”). The financial report therein is prepared in accordance with the PRC Accounting Standards for Business Enterprises and is unaudited.

By order of the Board

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Chen Yuqing

Chairman

Shanghai, the PRC

27 October 2026

As at the date of this announcement, the executive directors of the Company are Mr. Chen Yuqing, Ms. Guan Xiaohui, Mr. Wen Deyong, Mr. Wang Kexin and Mr. Liu Yi; the non-executive directors of the Company are Mr. Chen Qiyu and Mr. Pan Donghui; the independent non-executive directors of the Company are Mr. Yu Tze Shan Hailson, Mr. Wang Quandi, Mr. Chen Penghui and Mr. Yang Yucheng; and the employee director of the Company is Ms. Yan Jia.

* For identification purposes only

I. IMPORTANT NOTICE

The board of directors (the “**Board**”) of the Company and its directors and senior management warrant that the quarterly report does not contain any false information, misleading statements or material omission and severally and jointly accept legal responsibility for the truthfulness, accuracy and completeness of the contents contained herein.

The person in charge of the Company, the chief financial officer of the Company, and the director of the accounting department (accounting officer) of the Company warrant the truthfulness, accuracy and completeness of the financial information contained in the quarterly report.

The financial statements for the third quarter of 2026 of the Group are unaudited.

II. MAJOR FINANCIAL INFORMATION OF THE GROUP

(I) Major accounting information and financial indicators

Unit: Yuan Currency: RMB

Item	The Reporting Period	Increase or decrease in the Reporting Period compared with the corresponding period of last year (%)	From the beginning of the year to the end of the Reporting Period	Increase or decrease from the beginning of the year to the end of the Reporting Period over the corresponding period of last year (%)
Operating revenue	10,021,058,949.95 ^{Note 1}	1.44	30,463,029,335.95	3.64
Total profit	1,292,201,118.53	15.49	3,878,773,025.46	1.08
Net profit attributable to shareholders of the listed company	946,023,451.45	15.18	2,667,491,171.03	5.71
Net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss	561,502,871.13 ^{Note 2}	-8.32	1,705,668,606.18	8.42
Net cash flow generated from operating activities	1,003,149,714.16 ^{Note 3}	-19.60	3,427,102,128.84	1.34
Basic earnings per share (yuan/share)	0.36	16.13	1.01	6.32
Diluted earnings per share (yuan/share)	0.36	16.13	1.01	6.32
Weighted average return on net assets	1.89%	Increase by 0.17 percentage point	5.42%	Increase by 0.12 percentage point
	At the end of the Reporting Period	At the end of last year		Increase or decrease at the end of the Reporting Period compared with the end of last year (%)
Total assets	126,786,736,950.10	120,053,968,926.05		5.61
Equity attributable to shareholders of the listed company	50,304,754,985.57	48,741,507,004.70		3.21

Note 1: During the Reporting Period, operating revenue increased by 1.44% period-on-period. Excluding the impact of exchange rate fluctuations and calculated at constant exchange rates, it increased by 3.75% period-on-period, mainly driven by the growth of revenue from Innovative Drugs¹.

1 For the purpose of this report, mainly include innovative drugs, biosimilars, improved new drugs and other drugs with high technological barriers formed through technological innovation, the same below.

Innovative Drugs include: Trastuzumab for injection (Brand name in Chinese mainland: Han Qu You) and trastuzumab drug substance, Han Li Kang (rituximab injection), Serplulimab injection (Brand name in Chinese mainland: Han Si Zhuang), Akynzeo (netupitant and palonosetron hydrochloride capsules), Yi Kai Da (ejilunsai injection), Yi Xin Tan (sacubitril valsartan sodium tablets), Han Bei Tai (bevacizumab injection), Han Nai Jia (neratinib maleate tablets), Bei Wen (keverprazan hydrochloride tablets), Pei Jin (telpegfilgrastim injection), Su Ke Xin (avatrombopag maleate tablets), Han Da Yuan (adalimumab injection), Pu Rui Ni (pretomanid tablets), DAXXIFY (botulinum toxin type A for injection), Fu Ke Shu (anti-human T-lymphocyte rabbit immunoglobulin), Fu Mai Ning (lucvometinib tablets), Otezla (apremilast tablets), Denosumab Injection, Fu Tuo Ning (fovinaciclib citrate capsules), Han Bei You (pertuzumab injection), Wan Ti Le (tenapanor hydrochloride tablets), Pang Bi Fu (etelcalcetide hydrochloride injection), etc.

Note 2: During the Reporting Period, the net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss decreased by 8.32% period-on-period. Excluding the impact of exchange rate fluctuations and calculated at constant exchange rates, it decreased by 6.25% period-on-period. The period-on-period decrease in the net profit attributable to shareholders of the listed company after deducting extraordinary gain or loss was mainly attributable to the combined effects of the following factors: (1) the profit contribution from out-licensing projects in the corresponding period of last year, which raised the profit base for the prior period; (2) the period-on-period decrease in the share of results of associates and joint ventures; and (3) the period-on-period increase in exchange losses.

Note 3: During the Reporting Period, the period-on-period decrease in net cash flow generated from operating activities was mainly due to the receipt of a one-off upfront payment for license-out projects in the corresponding period of last year, which raised the cash flow base for the prior period.

(II) Extraordinary gain or loss items and amounts

Unit: Yuan Currency: RMB

Extraordinary gain or loss items	Amount of the period	Amount from the beginning of the year to the end of the Reporting Period
Gain or loss on disposal of non-current assets, including the written-off portion of provision for asset impairment	63,145,290.14	196,951,531.16
Government grants included in profit or loss for the current period, excluding government grants closely related to the company's normal operation, in line with national policies, entitled in accordance with the determined standards, and having a continuous impact on the company's profit or loss	50,929,649.54	117,980,423.04
Gain or loss arising from changes in fair value of financial assets and financial liabilities held by non-financial enterprises and gain or loss arising from disposal of financial assets and financial liabilities, except effective hedging business related to the company's normal operations	307,492,336.22	778,497,317.45
Share-based payment expenses recognised on a one-off basis arising from the cancellation or modification of the equity incentive scheme	—	–34,066,701.26
Non-operating income and expenses other than those stated above	–20,880,880.58	–50,250,049.04
Other gain or loss items that meet the definition of extraordinary gain or loss	—	33,668,429.56
Less: Effect of income tax	8,185,609.23	54,784,686.44
Impact on non-controlling interests (after tax)	7,980,205.77	26,173,699.62
Total	384,520,580.32	961,822,564.85

For extraordinary gain or loss items not stated in the “Explanatory Announcement No. 1 on Information Disclosure by Public Issuers of Securities — Extraordinary Gain or Loss” that are recognized as extraordinary gain or loss items with a material amount, and extraordinary gain or loss items stated in the “Explanatory Announcement No. 1 on Information Disclosure by Public Issuers of Securities — Extraordinary Gain or Loss” that are defined as recurring gain or loss items, the company shall provide the reasons.

Not applicable

(III) Changes in the principal accounting information and financial indicators and reasons for the changes

Not applicable

III. SHAREHOLDER INFORMATION

(I) Total number of holders of ordinary shares and holders of preference shares with resumed voting rights, and the shareholding status of the top 10 shareholders

Unit: Share

Total number of holders of ordinary shares as at the end of the Reporting Period	222,868	Total number of holders of preference shares with resumed voting rights as at the end of the Reporting Period (if any)	N/A			
The shareholding status of the top 10 shareholders (excluding shares lent through refinancing)						
Name of shareholders	Nature of shareholders	Shareholding	Percentage of shareholding (%)	Number of restricted shares held	Shares pledged, marked or locked up	
					Status	Number
Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) ^{Note 1}	Domestic non-state owned legal entity	889,890,955	33.32	0	Pledged	602,000,000
HKSCC NOMINEES LIMITED ^{Note 2}	Unknown	551,505,974	20.65	0	Unknown	—
Hong Kong Securities Clearing Company Limited ^{Note 3}	Others	43,429,168	1.63	0	None	0
Xiong Liwu (熊立武)	Domestic natural person	20,340,000	0.76	0	None	0
Bank of Shanghai Co., Ltd. — Yinhua CSI Innovative Drug Industry Trading Open-ended Index Securities Investment Fund* (上海銀行股份有限公司 — 銀華中證創新藥產業交易型開放式指數證券投資基金)	Securities investment fund	20,011,915	0.75	0	None	0
Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行股份有限公司 — 招商國證生物醫藥指數分級證券投資基金)	Securities investment fund	17,974,518	0.67	0	None	0
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-ended Index Securities Investment Fund* (中國建設銀行股份有限公司 — 易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	Securities investment fund	16,264,499	0.61	0	None	0
Bank of China Limited — GF China Securities Innovative Drug Industry Trading Open-ended Index Securities Investment Fund* (中國銀行股份有限公司 — 廣發中證創新藥產業交易型開放式指數證券投資基金)	Securities investment fund	13,195,254	0.49	0	None	0
National Social Security Fund Portfolio 113 (全國社保基金一一三組合)	Others	12,849,130	0.48	0	None	0
CSC Financial Co., Ltd. — Tianhong National Securities Biomedical Trading Open-ended Index Securities Investment Fund* (中信建投證券股份有限公司 — 天弘國證生物醫藥交易型開放式指數證券投資基金)	Securities investment fund	9,734,000	0.36	0	None	0

The shareholding status of the top 10 unrestricted shareholders (excluding shares lent through refinancing)			
Name of shareholders	Number of unrestricted tradable shares held	Type and number of shares	
		Type of shares	Number
Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) ^{Note 1}	889,890,955	RMB ordinary shares	889,890,955
HKSCC NOMINEES LIMITED ^{Note 2}	551,505,974	Overseas listed foreign shares	551,505,974
Hong Kong Securities Clearing Company Limited ^{Note 3}	43,429,168	RMB ordinary shares	43,429,168
Xiong Liwu (熊立武)	20,340,000	RMB ordinary shares	20,340,000
Bank of Shanghai Co., Ltd. — Yinhua CSI Innovative Drug Industry Trading Open-ended Index Securities Investment Fund* (上海銀行股份有限公司 — 銀華中證創新藥產業交易型開放式指數證券投資基金)	20,011,915	RMB ordinary shares	20,011,915
Bank of China Limited — China Merchants National Securities Biomedical Index Classified Securities Investment Fund* (中國銀行股份有限公司 — 招商國證生物醫藥指數分級證券投資基金)	17,974,518	RMB ordinary shares	17,974,518
China Construction Bank Corporation — E Fund CSI 300 Medical and Healthcare Trading Open-ended Index Securities Investment Fund* (中國建設銀行股份有限公司 — 易方達滬深300醫藥衛生交易型開放式指數證券投資基金)	16,264,499	RMB ordinary shares	16,264,499
Bank of China Limited — GF China Securities Innovative Drug Industry Trading Open-ended Index Securities Investment Fund* (中國銀行股份有限公司 — 廣發中證創新藥產業交易型開放式指數證券投資基金)	13,195,254	RMB ordinary shares	13,195,254
National Social Security Fund Portfolio 113 (全國社保基金一一三組合)	12,849,130	RMB ordinary shares	12,849,130
CSC Financial Co., Ltd. — Tianhong National Securities Biomedical Trading Open-ended Index Securities Investment Fund* (中信建投證券股份有限公司 — 天弘國證生物醫藥交易型開放式指數證券投資基金)	9,734,000	RMB ordinary shares	9,734,000
Description of the related relationship or concerted action of the above shareholders	As at the end of the Reporting Period, except for holding 889,890,955 A shares of the Company, Shanghai Fosun High Technology (Group) Company Limited* (上海復星高科技(集團)有限公司) (“ Fosun High Tech ”), the controlling shareholder of the Company, and its controlling shareholder, Fosun International Limited (“ Fosun International ”), held 71,533,500 and 6,000,000 H shares of the Company through HKSCC NOMINEES LIMITED, respectively. Save as disclosed above, the Company is not aware whether any related relationship or concerted action exists between other abovementioned shareholders of tradable shares.		
Description of top 10 shareholders and top 10 unrestricted shareholders participating in securities margin trading and refinancing business (if any)	Not applicable		

Note: Explanation on share repurchase special accounts among the top 10 shareholders: (1) The top 10 shareholders presented above have excluded the Company's A-share repurchase special account; (2) The shareholding of HKSCC NOMINEES LIMITED includes 22,333,500 H shares held in the Company's H-share repurchase account as treasury shares.

Note 1: The figures presented herein represent A shares only. As at the end of the Reporting Period, Fosun High Tech, the controlling shareholder of the Company, held an aggregate of 961,424,455 shares of the Company (including 889,890,955 A shares and 71,533,500 H shares), representing approximately 36.00% of the total share capital of the Company (i.e. 2,670,429,325 shares, the same hereinafter) as at the end of the Reporting Period.

Note 2: HKSCC NOMINEES LIMITED, i.e. Hong Kong Securities Clearing Company Nominees Limited, is holding shares on behalf of multiple clients (shares held by it at the end of the Reporting Period include an aggregate of 77,533,500 H shares of the Company held by Fosun High Tech, the controlling shareholder of the Company, and its controlling shareholder, Fosun International, through it, representing approximately 2.90% of the total share capital of the Company as at the end of the Reporting Period).

Note 3: Hong Kong Securities Clearing Company Limited is the nominee holder of the RMB ordinary shares under Shanghai-Hong Kong Stock Connect.

Shareholders holding more than 5% of the shares, the top 10 shareholders and the top 10 shareholders with unrestricted tradable shares involved in the shares lent through refinancing business

Not applicable

Changes in the top 10 shareholders and the top 10 shareholders with unrestricted tradable shares due to shares lent/returned through refinancing business as compared with the previous period

Not applicable

IV. OTHER REMINDER

The investors are reminded to pay attention to other significant information concerning the Group's operations during the Reporting Period

(I) Overview of operating results

In the first three quarters of 2026, the Group achieved a revenue of RMB30,463 million, representing a period-on-period increase of 3.64%. Excluding the impact of exchange rate fluctuations and calculated on constant exchange rates, the period-on-period increase was 5.81%. Among which: revenue from Innovative Drugs increased by 15.54% period-on-period, accounting for 35.43% of the pharmaceutical manufacturing business revenue, representing an increase of 3.11 percentage points compared with the same period of last year; overseas business revenue increased by 11.62% period-on-period, with its proportion of the Group's total revenue increasing to 30.96%, up by 2.21 percentage points compared with the same period of last year.

In the first three quarters of 2026, the Group's total R&D expenditure amounted to RMB5,247 million, representing a period-on-period increase of 31.24%, of which R&D expenses amounted to RMB3,118 million, representing a period-on-period increase of 14.21%. R&D expenditure in the pharmaceutical manufacturing business amounted to RMB4,954 million, representing a period-on-period increase of 38.30%, of which R&D expenses amounted to RMB2,839 million, representing a period-on-period increase of 19.89%. In the first three quarters of 2026, R&D expenditure related to Innovative Drugs reached RMB4,346 million, representing a year-on-year increase of 55.07%. R&D expenditure in Innovative Drugs accounted for 82.83% of the Group's total R&D expenditure, up by 12.73 percentage points from the corresponding period of last year; and accounted for 87.73% of the R&D expenditure in the pharmaceutical manufacturing business, up by 9.49 percentage points period-on-period, indicating that resources are continuously tilting towards innovative drugs.

During the third quarter of 2026, the Group continued to advance its innovation-driven transformation. During the Reporting Period, a total of 2 indications of 2 Innovative Drugs were approved for launch; the new drug application (“NDA”) for 1 Innovative Drug has been accepted; and 5 clinical trial applications for Innovative Drugs were approved (please refer to the table below), of which:

Wei Ke Tuo (Velinotamig Injection), which is laid out through licensing, has been approved with conditions by the National Medical Products Administration (the “NMPA”), for the indication of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy (including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody).

The additional indication of Fu Mai Ning (Luvometinib Tablets) has been approved by the NMPA. The newly approved indication is for adult patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection. Accordingly, the approved indications for this drug now cover patients across all age groups, further consolidating its leading position in this therapeutic area.

The NDA for HLX14, a biosimilar of denosumab (being recombinant anti-RANKL human monoclonal antibody injection) for the 120 mg (1.7 mL) per vial strength, has been accepted by the NMPA. The proposed indications include: (1) bone metastases from solid tumors and multiple myeloma; and (2) giant cell tumor of bone.

Among Innovative Drugs newly approved for clinical trials during the Reporting Period, Phase I clinical trials have been initiated in Chinese Mainland² during the quarter for the following: FXR0906, a liver-targeted siRNA (small interfering RNA) drug; DM1001; HLX37 (recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in combination with chemotherapy or HLX43 (an anti-PD-L1 antibody-drug conjugate); Phase II clinical trial of HLX43 (an anti-PD-L1 antibody-drug conjugate) in combination with bevacizumab, with or without chemotherapy has been initiated in Chinese Mainland during the quarter.

Meanwhile, the Group continues to advance global two-way license and co-development, and strengthen its capabilities for the integration of innovation resources and the translation of the global value. During the Reporting Period, Shanghai Henlius Biotech, Inc.* (上海復宏漢霖生物技術股份有限公司) (“**Shanghai Henlius**”), a subsidiary, entered into a collaboration framework agreement with Sandoz AG, pursuant to which, the parties may conduct licensing collaboration in relation to the registration, commercialization, development and manufacturing of up to ten monoclonal antibody (mAb) and/or antibody-drug conjugate (ADC) biosimilar products or components of Shanghai Henlius (the “Collaboration Product(s)”) in certain overseas territories. Specific commercial terms have been agreed for the first batch of three Collaboration Products (namely HLX05-N, HLX16 and a belimumab biosimilar), and an option has been granted to Sandoz AG in respect of one potential Collaboration Product (namely HLXTE-HAase1001). In addition, Shanghai Henlius has been granted an exclusive license based on the T-MATETM technology platform³ for the research, development, manufacturing and commercialization of two products targeting specified targets (being T Cell Engager (TCE) products).

² Excluding Hong Kong, Macau and Taiwan regions; the same hereinafter.

³ Being the Tumor Microenvironment Activated ThErapeutics platform, a proprietary tumor microenvironment activated technology platform of the licensor.

Table: Major Pipeline Progress Achieved during the Reporting Period

Progress during the Reporting Period	Drug name/code	Target	Drug category	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch
Approved for launch	Velinotamig Injection (Brand Name in Chinese mainland: Wei Ke Tuo)	BCMA×CD3	Therapeutic biological product	Adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy (including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody)						
	Luvometinib Tablets (Brand Name in Chinese mainland: Fu Mai Ning)	MEK1/2	Chemical drug	The additional indication: adult patients with neurofibromatosis type 1 (NF1) who have symptomatic plexiform neurofibromas (PN) not amenable to complete resection						
NDA accepted	HLX14 (Denosumab Injection) (Specification: 120mg (1.7ml)/vial)	RANKL	Therapeutic biological product	(1) Bone metastases from solid tumors and multiple myeloma: for the treatment of patients with bone metastases from solid tumors or multiple myeloma, to delay or reduce the risk of skeletal-related events (pathological fractures, spinal cord compression, radiation therapy to bone, or surgery to bone); (2) giant cell tumor of bone: for the treatment of giant cell tumor of bone that is unresectable or for which surgical resection is likely to result in severe functional impairment, including adults and adolescent patients with a mature skeleton (defined as having at least one mature long bone and body weight ≥45 kg)						
Under phase II clinical study	FXS7553 (original project code: XH-S004)	DPP1	Chemical drug	Chronic obstructive pulmonary disease (COPD)						
	HLX43 (an anti-PD-L1 antibody-drug conjugate) in combination with bevacizumab, with or without chemotherapy*	PD-L1 ADC + VEGF	Therapeutic biological product	Advanced/metastatic solid tumors						

Table: Major Pipeline Progress Achieved during the Reporting Period (Continued)

Progress during the Reporting Period	Drug name/code	Target	Drug category	Indications	IND approved	Phase I	Phase II	Phase III	NDA accepted	Approved for launch
Under phase I clinical study	FXR0906*	APOC3	Chemical drug	Hypertriglyceridemia						
	DM1001*	Dopamine receptor	Chemical drug	For the treatment of signs and symptoms of idiopathic Parkinson's disease in adults						
	HLX3902 (STEAP×CD3×CD28 trispecific antibody)	STEAP1×CD3×CD28	Therapeutic biological product	Metastatic castration-resistant prostate cancer and other advanced solid tumors						
	HLX18 (Recombinant anti-PD-1 humanized monoclonal antibody injection)	PD-1	Therapeutic biological product	Solid tumors						
	HLX05-N (Recombinant anti-EGFR chimeric human-murine monoclonal antibody injection)	EGFR	Therapeutic biological product	Metastatic colorectal cancer						
	HLX37 (Recombinant humanized anti-PD-L1 and anti-VEGF bispecific antibody injection) in combination with chemotherapy or HLX43 (an anti-PD-L1 antibody-drug conjugate)*	PD-L1×VEGF +PD-L1 ADC	Therapeutic biological product	Advanced/metastatic solid tumors						
IND approved	FXS5626 (original project code: AC-201)	TYK2/JAK1	Chemical drug	Non-segmental vitiligo						

* Refers to investigational drugs that were approved for clinical trials and entered the corresponding clinical study stages during the Reporting Period.

Note: Unless otherwise specified, the pipeline progress set out above relates to developments within Chinese mainland.

(II) Others

1. *The 2026 H Share Repurchase Plan and the Implementation Progress*

Based on confidence in the Group's development prospects and in recognition of its intrinsic value, pursuant to the general mandate to repurchase H shares of the Company approved at the 2025 annual general meeting, the 2026 second A shareholders' class meeting and the 2026 second H shareholders' class meeting of the Company respectively, and upon the approvals of the Board, the Company has proposed to repurchase its H shares during the 12 months commencing from 27 August 2026, with the proposed total amount of funds for repurchase of up to HK\$1 billion.

As at the end of the Reporting Period, under the repurchase plan, the Company had repurchased an aggregate of 11,364,500 H shares (representing approximately 0.43% of the total share capital of the Company as at the close of business on that date), with an aggregate repurchase amount of approximately HK\$194.0662 million, at a highest price of HK\$18.23 per share, a lowest price of HK\$16.01 per share and an average price of HK\$17.08 per share.

2. *Reserved Grant under the 2025 A Share Option Incentive Scheme*

Pursuant to the 2025 A Share Option Incentive Scheme and the related mandates approved at the 2025 first extraordinary general meeting of the Company, the Board agreed to designate 28 August 2026 as the reserved grant date and to grant an aggregate of 725,100 A share options to a total of 100 participants of the reserved grant. During the execution of the grant agreements, save for one participant of the reserved grant who had ceased to hold any position with the Group and thus no longer fell within the scope of eligible participants under the scheme, the Company ultimately granted an aggregate of 723,300 A share options to a total of 99 participants. Such A share options were registered with the Shanghai Branch of China Securities Depository and Clearing Corporation Limited on 24 September 2026.

3. *Reserved Grant under the 2025 H Share RSU Scheme*

Pursuant to the 2025 H Share RSU Scheme and the related mandates approved at the 2025 first extraordinary general meeting of the Company, the Board agreed to designate 28 August 2026 as the reserved grant date and to grant an aggregate of 1,695,400 H share restricted share units ("RSUs") to a total of 100 eligible employees. During the execution of the grant agreements, save for one participant of the reserved grant who had ceased to hold any position with the Group and thus no longer fell within the scope of eligible employees under the scheme, the Company ultimately granted an aggregate of 1,691,200 H share RSUs to a total of 99 eligible employees.

V. QUARTERLY FINANCIAL STATEMENTS

(I) Types of audit opinion

Not applicable

(II) Financial statements

Consolidated Balance Sheet

30 September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2026	31 December 2025
Current assets:		
Cash and bank balances	13,297,438,407.28	13,104,229,127.57
Financial assets held for trading	2,459,969,064.60	2,253,869,614.45
Bills receivable	24,335,157.18	62,368,108.98
Trade receivables	9,579,435,445.73	9,364,522,148.66
Receivables financing	266,372,998.64	411,548,144.17
Prepayments	1,180,811,451.67	877,861,097.13
Other receivables	864,591,766.99	703,080,186.95
Including: Interest receivable	87,991,675.53	106,738,571.13
Dividends receivable	4,293,206.32	4,293,206.32
Inventories	5,998,289,759.68	6,252,472,423.26
Contract assets	144,710,967.74	116,367,018.30
Other current assets	727,283,124.26	674,353,460.80
Total current assets	34,543,238,143.77	33,820,671,330.27
Non-current assets:		
Long-term receivables	231,899,539.05	213,538,840.62
Long-term equity investments	28,801,767,868.12	26,371,624,822.71
Other equity instrument investments	15,614,159.75	19,218,079.20
Other non-current financial assets	885,926,153.95	878,423,850.04
Fixed assets	17,915,821,379.48	17,977,270,621.16
Construction in progress	3,218,746,139.33	3,055,431,191.79
Right-of-use assets	2,740,262,261.30	3,051,142,409.26
Intangible assets	14,443,292,362.79	13,999,154,273.18
Development expenditures	8,484,184,481.16	5,944,272,243.19
Goodwill	10,759,916,289.02	10,809,757,475.70
Long-term deferred expenditures	1,536,890,986.27	1,648,230,240.12
Deferred tax assets	937,338,340.78	985,336,662.52
Other non-current assets	2,271,838,845.33	1,279,896,886.29
Total non-current assets	92,243,498,806.33	86,233,297,595.78
Total assets	126,786,736,950.10	120,053,968,926.05

Consolidated Balance Sheet (Continued)
30 September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2026	31 December 2025
Current liabilities:		
Short-term loans	15,489,208,100.53	15,529,939,564.82
Bills payable	298,991,322.51	287,969,249.24
Trade payable	4,278,636,795.07	4,856,044,809.37
Contract liabilities	1,067,236,815.81	1,299,979,017.80
Wages payable	1,920,449,670.06	2,274,748,061.66
Tax payable	461,858,186.46	544,690,173.60
Other payables	4,136,707,384.91	3,830,522,355.53
Including: Interest payable	—	—
Dividends payable	16,043,354.09	22,599,525.89
Non-current liabilities due within one year	7,467,788,196.30	7,649,540,310.51
Other current liabilities	182,573,149.12	150,882,536.31
Total current liabilities	35,303,449,620.77	36,424,316,078.84
Non-current liabilities:		
Long-term loans	14,347,342,798.93	10,361,990,716.66
Bonds payable	1,100,000,000.00	1,500,000,000.00
Lease liabilities	2,777,937,936.41	3,050,771,401.85
Long-term payables	308,057,244.24	476,361,675.65
Long-term wages payable	111,851,484.63	113,639,028.43
Deferred income	589,861,690.70	653,383,367.96
Deferred tax liabilities	3,224,134,804.62	3,259,805,775.15
Other non-current liabilities	2,950,232,445.13	2,373,351,030.17
Total non-current liabilities	25,409,418,404.66	21,789,302,995.87
Total liabilities	60,712,868,025.43	58,213,619,074.71
Owners' equity (or shareholders' equity):		
Share capital	2,670,429,325.00	2,670,429,325.00
Capital reserve	17,313,792,633.42	16,376,932,223.95
Less: Treasury shares	775,035,622.40	607,963,682.55
Other comprehensive income	-2,614,129,573.02	-1,768,949,595.54
Surplus reserve	3,012,719,177.40	3,012,719,177.40
Unappropriated profit	30,696,979,045.17	29,058,339,556.44
Total equity attributable to the owners (or shareholders) of the parent company	50,304,754,985.57	48,741,507,004.70
Non-controlling interests	15,769,113,939.10	13,098,842,846.64
Total owners' equity (or shareholders' equity)	66,073,868,924.67	61,840,349,851.34
Total liabilities and owners' equity (or shareholders' equity)	126,786,736,950.10	120,053,968,926.05

*Person in charge of
the Company:*
Chen Yuqing

Chief Financial Officer:
Huang Zhi

*Director of
the Accounting Department:*
Zhou Qin

Consolidated Income Statement
January — September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2026 (Jan-Sep)	First three quarters of 2025 (Jan-Sep)
I. Total operating revenue	30,463,029,335.95	29,393,385,360.91
Including: Operating revenue	30,463,029,335.95	29,393,385,360.91
II. Total operating costs	29,215,995,428.44	28,415,595,587.60
Including: Operating costs	15,319,947,919.23	15,225,462,362.51
Tax and surcharges	231,500,417.23	240,949,647.30
Selling and distribution expenses	6,493,287,511.70	6,269,283,998.05
General and administrative expenses	3,194,235,720.33	3,067,356,397.76
Research and development expenses	3,118,159,904.98	2,729,517,164.80
Finance costs	858,863,954.97	883,026,017.18
Including: Interest expenses	921,658,287.27	974,025,974.09
Interest income	194,979,641.52	236,793,412.05
Plus: Other income	224,604,284.43	277,406,532.99
Investment income (“–” indicating loss)	2,060,239,071.22	3,095,360,303.24
Including: Investment income from associates and joint ventures	1,538,519,952.82	1,400,858,302.87
Gains from changes in fair value (“–” indicating loss)	483,573,186.63	–375,106,548.93
Credit impairment losses (“–” indicating loss)	–58,987,157.63	–47,122,378.60
Asset impairment losses (“–” indicating loss)	–28,630,519.49	–84,326,905.63
Gains from disposal of assets (“–” indicating loss)	1,190,301.82	62,764,603.19
III. Operating profit (“–” indicating loss)	3,929,023,074.49	3,906,765,379.57
Plus: Non-operating income	32,795,362.41	17,991,026.97
Less: Non-operating expenses	83,045,411.44	87,412,924.75
IV. Total profit (“–” indicating total loss)	3,878,773,025.46	3,837,343,481.79
Less: Income tax expenses	631,656,748.34	781,251,530.11
V. Net profit (“–” indicating net loss)	3,247,116,277.12	3,056,091,951.68
(I) Classification according to the continuity of operation		
1. Net profit from continuing operations (“–” indicating net loss)	3,247,116,277.12	3,056,091,951.68
2. Net profit from discontinued operations (“–” indicating net loss)	—	—
(II) Classification according to ownership		
1. Net profit attributable to the owners of the parent company (“–” indicating net loss)	2,667,491,171.03	2,523,293,508.22
2. Profit or loss attributable to non-controlling interests (“–” indicating net loss)	579,625,106.09	532,798,443.46

Consolidated Income Statement (Continued)

January — September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2026 (Jan-Sep)	First three quarters of 2025 (Jan-Sep)
VI. Other comprehensive income, net of tax	-1,264,587,213.04	-385,229,723.22
(I) Other comprehensive income attributable to the owners of the parent company, net of tax	-845,179,977.48	-280,830,700.90
1. Other comprehensive income not reclassified subsequently to profit or loss	-3,126,185.13	4,588,718.79
(1) Changes arising from remeasurement of defined benefit plan	—	—
(2) Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	—
(3) Change in the fair value of other equity instrument investments	-3,126,185.13	4,588,718.79
(4) Change in fair value of credit risk of the Company	—	—
(5) Others	—	—
2. Other comprehensive income reclassified subsequently to profit or loss	-842,053,792.35	-285,419,419.69
(1) Other comprehensive income using the equity method that will be reclassified to profit or loss	-94,695,090.98	-91,935,848.39
(2) Changes in fair value of other debt investments	—	—
(3) Amount of financial assets reclassified into other comprehensive income	—	—
(4) Credit impairment provisions for other debt investments	—	—
(5) Reserves for cash flow hedges	—	—
(6) Exchange differences on translation of financial statement in foreign currency	-747,358,701.37	-193,483,571.30
(7) Others	—	—
(II) Other comprehensive income attributable to non-controlling interests, net of tax	-419,407,235.56	-104,399,022.32
VII. Total comprehensive income	1,982,529,064.08	2,670,862,228.46
(I) Total comprehensive income attributable to the owners of the parent company	1,822,311,193.55	2,242,462,807.32
(II) Total comprehensive income attributable to non-controlling interests	160,217,870.53	428,399,421.14
VIII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	1.01	0.95
(II) Diluted earnings per share (yuan/share)	1.01	0.95

Person in charge of
the Company:
Chen Yuqing

Chief Financial Officer:
Huang Zhi

Director of
the Accounting Department:
Zhou Qin

Consolidated Statement of Cash Flow
January — September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2026 (Jan-Sep)	First three quarters of 2025 (Jan-Sep)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	30,850,945,235.68	30,773,141,374.91
Refund of taxes and levies	267,121,236.18	253,122,403.14
Other cash received relating to operating activities	1,539,814,117.78	1,185,817,322.69
Sub-total of cash inflow generated from operating activities	32,657,880,589.64	32,212,081,100.74
Cash paid for purchasing goods and receiving services	10,365,480,198.27	11,176,691,619.61
Cash paid to and on behalf of employees	9,064,786,805.05	8,507,722,635.45
Cash paid for all types of taxes	2,001,691,097.55	2,054,188,939.25
Other cash paid relating to operating activities	7,798,820,359.93	7,091,709,340.72
Sub-total of cash outflow generated from operating activities	29,230,778,460.80	28,830,312,535.03
Net cash flow generated from operating activities	3,427,102,128.84	3,381,768,565.71
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	910,761,411.30	2,217,629,391.75
Cash received from returns on investments	215,883,869.08	226,566,471.52
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	54,656,114.37	42,136,833.16
Net cash received from disposal of subsidiaries and other operating segments	100,201,800.24	181,376,314.58
Other cash received relating to investing activities	249,633,071.12	220,302,827.77
Sub-total of cash inflow generated from investing activities	1,531,136,266.11	2,888,011,838.78
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	4,266,574,045.04	3,168,540,323.03
Cash paid for investments	1,736,899,943.37	892,030,051.91
Net cash paid for acquisition of subsidiaries and other operating segments	324,166,869.10	33,976,446.70
Other cash paid relating to investing activities	762,542,195.04	305,297,457.93
Sub-total of cash outflow generated from investing activities	7,090,183,052.55	4,399,844,279.57
Net cash flow generated from investing activities	-5,559,046,786.44	-1,511,832,440.79

Consolidated Statement of Cash Flow (Continued)*January — September 2026***Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.***

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2026 (Jan-Sep)	First three quarters of 2025 (Jan-Sep)
III. Cash flow generated from financing activities:		
Cash received from capital contribution	197,048,347.01	195,288,551.57
Including: Cash received by subsidiaries from investments of non-controlling interests	197,048,347.01	195,288,551.57
Cash received from borrowings	24,403,973,463.19	26,346,546,129.08
Other cash received relating to financing activities	2,455,019,083.03	327,480,095.01
Sub-total of cash inflow generated from financing activities	27,056,040,893.23	26,869,314,775.66
Cash paid for debts settlement	21,093,000,252.69	26,629,633,045.31
Cash paid for the distribution of dividends, profits or interest	2,269,952,749.06	2,060,586,501.09
Including: Dividends and profits paid by subsidiaries to non-controlling interests	305,119,877.81	351,893,007.84
Other cash paid relating to financing activities	709,740,578.83	1,423,521,850.45
Sub-total of cash outflow generated from financing activities	24,072,693,580.58	30,113,741,396.85
Net cash flow generated from financing activities	2,983,347,312.65	-3,244,426,621.19
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-319,036,554.60	-80,826,833.37
V. Net increase in cash and cash equivalents	532,366,100.45	-1,455,317,329.64
Plus: Opening balance of cash and cash equivalents	9,038,010,120.70	9,391,449,787.11
VI. Closing balance of cash and cash equivalents	9,570,376,221.15	7,936,132,457.47

*Person in charge of
the Company:*
Chen Yuqing

Chief Financial Officer:
Huang Zhi

*Director of
the Accounting Department:*
Zhou Qin

Balance Sheet of the Parent Company
30 September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2026	31 December 2025
Current assets:		
Cash and bank balances	962,863,219.34	1,769,966,580.28
Financial assets held for trading	118,809,711.22	116,424,248.71
Bills receivable	100,000,000.00	95,000,000.00
Other receivables	1,646,278,767.98	1,228,691,214.28
Including: Interest receivable	—	—
Dividends receivable	4,293,206.32	4,293,206.32
Non-current assets due within one year	4,724,735,188.55	3,798,584,086.69
Other current assets	709,730,199.28	744,977,018.41
Total current assets	8,262,417,086.37	7,753,643,148.37
Non-current assets:		
Long-term equity investments	42,122,667,548.29	40,729,348,273.33
Other non-current financial assets	2,843,101.91	2,924,596.99
Fixed assets	4,598,096.07	4,515,500.94
Construction in progress	—	36,316.98
Intangible assets	950,257.51	1,060,009.14
Other non-current assets	3,151,375,250.24	3,344,410,836.45
Total non-current assets	45,282,434,254.02	44,082,295,533.83
Total assets	53,544,851,340.39	51,835,938,682.20
Current liabilities:		
Short-term loans	6,724,972,579.94	6,714,057,459.37
Wages payable	150,095,777.40	172,562,934.30
Tax payable	29,020,387.08	36,235,955.43
Other payables	2,699,465,196.53	3,173,840,000.34
Including: Interest payable	—	—
Dividends payable	—	—
Non-current liabilities due within one year	2,128,217,177.78	649,148,477.77
Other current liabilities	102,520,524.87	144,873,508.04
Total current liabilities	11,834,291,643.60	10,890,718,335.25
Non-current liabilities:		
Long-term loans	2,770,733,244.83	2,581,940,478.17
Bonds payable	1,000,000,000.00	1,500,000,000.00
Deferred income	300,000.00	—
Deferred tax liabilities	1,151,018,873.79	1,151,018,873.79
Total non-current liabilities	4,922,052,118.62	5,232,959,351.96
Total liabilities	16,756,343,762.22	16,123,677,687.21

Balance Sheet of the Parent Company (*Continued*)
30 September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	30 September 2026	31 December 2025
Owners' equity (or shareholders' equity):		
Share capital	2,670,429,325.00	2,670,429,325.00
Capital reserve	18,826,172,905.64	18,742,541,576.71
Less: Treasury shares	775,035,622.40	607,963,682.55
Other comprehensive income	—414,545,479.06	—342,886,595.04
Surplus reserve	1,336,199,355.50	1,336,199,355.50
Unappropriated profit	15,145,287,093.49	13,913,941,015.37
Total owners' equity (or shareholders' equity)	36,788,507,578.17	35,712,260,994.99
Total liabilities and owners' equity (or shareholders' equity)	53,544,851,340.39	51,835,938,682.20

*Person in charge of
the Company:*
Chen Yuqing

Chief Financial Officer:
Huang Zhi

*Director of
the Accounting Department:*
Zhou Qin

Income Statement of the Parent Company

January — September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2026 (Jan-Sep)	First three quarters of 2025 (Jan-Sep)
I. Operating revenue	17,781,769.07	18,547,828.00
Less: Operating cost	3,134,405.79	2,945,094.32
Tax and surcharges	50,536.87	239,211.03
General and administrative expenses	218,892,700.88	164,210,969.48
Research and development expenses	6,267,443.45	14,624,164.84
Finance costs	238,376,351.51	201,247,476.39
Including: Interest expenses	298,343,167.19	294,163,226.16
Interest income	44,231,963.19	90,509,351.78
Investment income (“-” indicating loss)	2,710,129,802.50	1,410,111,048.58
Including: Investment income from associates and joint ventures	1,507,033,079.96	1,455,837,264.49
Gains from changes in fair value (“-” indicating loss)	3,064,767.50	-11,934,822.53
Gains from disposal of assets (“-” indicating loss)	22,682.86	—
II. Operating profit (“-” indicating loss)	2,264,277,583.43	1,033,457,137.99
Plus: Non-operating income	—	—
Less: Non-operating expenses	4,079,823.01	655,308.61
III. Total profit (“-” indicating total loss)	2,260,197,760.42	1,032,801,829.38
Less: Income tax expenses	—	22,267.07
IV. Net profit (“-” indicating net loss)	2,260,197,760.42	1,032,779,562.31
(I) Net profit from continuing operations (“-” indicating net loss)	2,260,197,760.42	1,032,779,562.31
(II) Net profit from discontinued operations (“-” indicating net loss)	—	—
V. Other comprehensive income, net of tax	-71,658,884.02	22,454,294.79
(I) Other comprehensive income not reclassified subsequently to profit or loss	—	—
1. Changes arising from remeasurement of defined benefit plan	—	—
2. Other comprehensive income using the equity method that will not be reclassified to profit or loss	—	—
3. Change in the fair value of other equity instrument investments	—	—
4. Change in fair value of credit risk of the Company	—	—
(II) Other comprehensive income reclassified subsequently to profit or loss	-71,658,884.02	22,454,294.79
1. Other comprehensive income using the equity method that will be reclassified to profit or loss	-71,658,884.02	22,454,294.79
2. Changes in fair value of other debt investments	—	—
3. Amount of financial assets reclassified into other comprehensive income	—	—
4. Credit impairment provisions for other debt investments	—	—
5. Reserves for cash flow hedges	—	—
6. Exchange differences on translation of financial statement in foreign currency	—	—
7. Others	—	—

Income Statement of the Parent Company (*Continued*)

January — September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2026 (Jan-Sep)	First three quarters of 2025 (Jan-Sep)
VI. Total comprehensive income	2,188,538,876.40	1,055,233,857.10
VII. Earnings per share:		
(I) Basic earnings per share (yuan/share)	N/A	N/A
(II) Diluted earnings per share (yuan/share)	N/A	N/A

*Person in charge of
the Company:*
Chen Yuqing

Chief Financial Officer:
Huang Zhi

*Director of
the Accounting Department:*
Zhou Qin

Statement of Cash Flow of the Parent Company

January — September 2026

Prepared by: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

Unit: Yuan Currency: RMB Type of audit: Unaudited

Items	First three quarters of 2026 (Jan-Sep)	First three quarters of 2025 (Jan-Sep)
I. Cash flow generated from operating activities:		
Cash received from sale of goods and rendering of services	22,738,327.40	15,440,917.83
Other cash received relating to operating activities	1,057,480,029.32	633,588,361.20
Sub-total of cash inflow generated from operating activities	1,080,218,356.72	649,029,279.03
Cash paid to and on behalf of employees	112,902,191.01	128,276,031.89
Cash paid for all types of taxes	154,986.62	397,727.94
Other cash paid relating to operating activities	74,037,619.10	104,043,311.49
Sub-total of cash outflow generated from operating activities	187,094,796.73	232,717,071.32
Net cash flow generated from operating activities	893,123,559.99	416,312,207.71
II. Cash flow generated from investing activities:		
Cash received from disposal of investments	4,624,350.09	35,354,920.03
Cash received from returns on investments	1,247,588,093.57	1,093,832,087.23
Net cash received from disposal of fixed assets, intangible assets and other long-term assets	107,930.65	24,100.00
Sub-total of cash inflow generated from investing activities	1,252,320,374.31	1,129,211,107.26
Cash paid for acquisition of fixed assets, intangible assets and other long-term assets	1,112,973.99	372,672.78
Cash paid for investments	6,800,000.00	341,529,604.31
Sub-total of cash outflow generated from investing activities	7,912,973.99	341,902,277.09
Net cash flow generated from investing activities	1,244,407,400.32	787,308,830.17
III. Cash flow generated from financing activities:		
Cash received from borrowings	7,617,962,862.92	9,611,300,029.24
Other cash received relating to financing activities	7,406,285,777.62	11,082,009,755.64
Sub-total of cash inflow generated from financing activities	15,024,248,640.54	20,693,309,784.88
Cash paid for debts settlement	6,440,136,380.41	8,655,654,938.60
Cash paid for the distribution of dividends, profits or interest	1,332,204,401.07	1,132,236,990.03
Other cash paid relating to financing activities	9,172,794,173.47	12,264,198,391.65
Sub-total of cash outflow generated from financing activities	16,945,134,954.95	22,052,090,320.28
Net cash flow generated from financing activities	-1,920,886,314.41	-1,358,780,535.40
IV. Effects of exchange rate fluctuations on cash and cash equivalents	-1,748,006.84	-104,151.49
V. Net increase in cash and cash equivalents	214,896,639.06	-155,263,649.01
Plus: Opening balance of cash and cash equivalents	747,966,580.28	612,741,668.27
VI. Closing balance of cash and cash equivalents	962,863,219.34	457,478,019.26

Person in charge of
the Company:
Chen Yuqing

Chief Financial Officer:
Huang Zhi

Director of
the Accounting Department:
Zhou Qin

(III) Status in relation to adjustments to the financial statements at the beginning of the year for the implementation of new accounting standards or interpretation of standards for the first time from 2026

Not applicable

By order of the Board
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*
Chen Yuqing
Chairman

Shanghai, the PRC
27 October 2026